EARLY DIAPAC: EARLY DIAgnosis of PAncreatic Cancer by combined proteomics and genomics testing of pancreatic cyst fluid. Nov 1, 2023 - Dec 31, 2024
This is part of a total project cost of £98,508.70.
EARLY DIAPAC: EARLY DIAgnosis of PAncreatic Cancer by combined proteomics and genomics testing of pancreatic cyst fluid. Nov 1, 2023 - Dec 31, 2024
This is part of a total project cost of £98,508.70.
Wolfson Equipment bid 2023 - Confocal Imaging ZEISS Elyra 7 with Lattice SIM² Oct 1, 2024 - Sep 30, 2029
ACF 2023-2026 Sep 1, 2023 - Aug 31, 2026
Quantitative proteomic analysis of pancreatic cyst fluid for early detection of cancer using University of Hull HPC Viper Apr 1, 2022 - Feb 28, 2023
The timely diagnosis of pancreatic ductal adenocarcinoma (PDAC) is challenging due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease and poor prognosis. Detection of PDAC, ideally at a prem...
Read More about Quantitative proteomic analysis of pancreatic cyst fluid for early detection of cancer using University of Hull HPC Viper.
EARLY DIAPAC: EARLY DIAgnosis of PAncreatic Cancer by combined proteomics and genomics testing of pancreatic cyst fluid. Dec 1, 2022 - Dec 31, 2024
This is part of a total project cost of £98,508.70.
SERENITY: Towards cancer patient empowerment for optimal use of antithrombotic therapy at the end of life Oct 1, 2022 - Sep 30, 2027
Molecular pathways of pancreatic cancer carcinogenesis from pancreatic cystic neoplasms to adenocarcinoma Sep 1, 2020 - Aug 31, 2023
Pancreatic cancer is one of the main research areas of expertise of Professor Maraveyas and his team. This is an exciting opportunity to work on molecular pathways in pancreatic tissue that reflect the early changes during carcinogenesis and transla...
Read More about Molecular pathways of pancreatic cancer carcinogenesis from pancreatic cystic neoplasms to adenocarcinoma.
Differentiating the malignant potential of pancreatic cysts Oct 1, 2017 - Dec 31, 2022
The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis. Earlier detection of pan...
Read More about Differentiating the malignant potential of pancreatic cysts.
A study of the incorporation and release of tissue factor as cancer cell-derived microparticles. Aug 1, 2014 - Jul 31, 2017
Can prevention of the activation of PAR2 prevent the release of procoagulant microvesicles from cancer cells, reduce the risk of VTE and contain the deterioration of the vasculature? Jul 1, 2015 - Jun 30, 2020
The study aims to demonstrate the indirect effect of Apixaban on suppressing the release of pro-inflammatory, pro-coagulant tissue factor-containing microvesicles, by inhibiting factor Xa and preventing the activation of PAR2. The study also demonstr...
Read More about Can prevention of the activation of PAR2 prevent the release of procoagulant microvesicles from cancer cells, reduce the risk of VTE and contain the deterioration of the vasculature?.
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search